Coiled Therapeutics PLC (COIL)

ORD 1P

Sell: 8.00p|Buy: 9.00p|Change: 0.32 (-3.76%)

Open

8.50p

Previous close

8.50p

Trade high

8.18p

Volume

5,710

Year high

9.50p

Year low

8.00p

Dividend yield

–

Market capitalisation

£13.39 mn

P/E ratio

–

ISIN

GB00BSHRN331

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPPand can be used with Dividend reinvestment

Share price

Performance

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Coiled Therapeutics PLC	0
More...

Company profile

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. The product portfolio of the company consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical development of next-generation medicines focused on hard-to-treat cancers.

Sector

Healthcare

News

Recent trades

Date	Time	Price	Quantity	Value (£)
07/04/2026	02:08:30	8.18	2,000	163.60
07/04/2026	12:25:35	8.18	3,142	257.02
07/04/2026	12:19:16	8.18	21	1.72
07/04/2026	10:17:48	8.17	537	43.87
07/04/2026	09:05:11	8.17	10	0.82

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.